BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31749595)

  • 21. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection.
    Shirai Y; Shiba H; Sakamoto T; Horiuchi T; Haruki K; Fujiwara Y; Futagawa Y; Ohashi T; Yanaga K
    Surgery; 2015 Aug; 158(2):360-5. PubMed ID: 26032829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre-operative dysglycemia is associated with decreased survival in patients with pancreatic neuroendocrine neoplasms.
    Sandini M; Strobel O; Hank T; Lewosinska M; Nießen A; Hackert T; Büchler MW; Schimmack S
    Surgery; 2020 Mar; 167(3):575-580. PubMed ID: 31889543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From the Immune Profile to the Immunoscore: Signatures for Improving Postsurgical Prognostic Prediction of Pancreatic Neuroendocrine Tumors.
    Wei M; Xu J; Hua J; Meng Q; Liang C; Liu J; Zhang B; Wang W; Yu X; Shi S
    Front Immunol; 2021; 12():654660. PubMed ID: 33968055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
    Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
    Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Response to: Platelet indices in differential diagnosis of pancreatic neuroendocrine tumors from pancreatic adenocarcinomas.
    Karaman K; Kurt M; Aksoy E
    Eur J Intern Med; 2014 Jul; 25(6):e83. PubMed ID: 24873725
    [No Abstract]   [Full Text] [Related]  

  • 28. [Analysis of diagnosis, therapy and prognosis factors of 103 patients with pancreatic neuroendocrine tumors].
    Luo Q; Liu YN; Ma HY; Li S; Huang JY; Li G; Jin G
    Zhonghua Wai Ke Za Zhi; 2017 Oct; 55(10):755-759. PubMed ID: 29050176
    [No Abstract]   [Full Text] [Related]  

  • 29. Peripheral Blood Lymphocytes and Platelets Are Prognostic in Surgical pT1 Non-Small Cell Lung Cancer.
    Sulibhavi A; Asokan S; Miller MI; Moreira P; Daly BD; Fernando HC; Litle VR; Suzuki K
    Ann Thorac Surg; 2020 Feb; 109(2):337-342. PubMed ID: 31593659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
    Lombardi M; De Lio N; Funel N; Sardella C; Russo D; Urbani C; Rossi G; Campani D; Martino E; Marcocci C; Boggi U; Bogazzi F
    J Endocrinol Invest; 2015 Jun; 38(6):605-13. PubMed ID: 25501604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum Elastase 1 Level as a Risk Factor for Postoperative Recurrence in Patients with Well-Differentiated Pancreatic Neuroendocrine Neoplasms.
    Nanno Y; Toyama H; Zen Y; Akita M; Ando Y; Mizumoto T; Ueda Y; Ajiki T; Okano K; Suzuki Y; Fukumoto T
    Ann Surg Oncol; 2018 Oct; 25(11):3358-3364. PubMed ID: 30054822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
    Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
    Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.
    Wei IH; Harmon CM; Arcerito M; Cheng DF; Minter RM; Simeone DM
    Ann Surg; 2014 Dec; 260(6):1088-94. PubMed ID: 25389924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place.
    de Mestier L; Gaujoux S; Cros J; Hentic O; Vullierme MP; Couvelard A; Cadiot G; Sauvanet A; Ruszniewski P; Richard S; Hammel P
    Ann Surg; 2015 Aug; 262(2):384-8. PubMed ID: 25185468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors.
    Genç CG; Jilesen AP; Partelli S; Falconi M; Muffatti F; van Kemenade FJ; van Eeden S; Verheij J; van Dieren S; van Eijck CHJ; Nieveen van Dijkum EJM
    Ann Surg; 2018 Jun; 267(6):1148-1154. PubMed ID: 28594340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
    Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
    J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis.
    Birnbaum DJ; Gaujoux S; Cherif R; Dokmak S; Fuks D; Couvelard A; Vullierme MP; Ronot M; Ruszniewski P; Belghiti J; Sauvanet A
    Surgery; 2014 Jan; 155(1):13-21. PubMed ID: 24238123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutrophil-to-lymphocyte ratio predicts metachronous liver metastasis of pancreatic neuroendocrine tumors.
    Arima K; Okabe H; Hashimoto D; Chikamoto A; Nitta H; Higashi T; Kaida T; Yamamura K; Kitano Y; Komohara Y; Yamashita YI; Beppu T; Takeya M; Baba H
    Int J Clin Oncol; 2017 Aug; 22(4):734-739. PubMed ID: 28285371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
    Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.